Blanco, Jorge C. G.
Pletneva, Lioubov M.
McGinnes-Cullen, Lori
Otoa, Raymonde O.
Patel, Mira C.
Fernando, Lurds R.
Boukhvalova, Marina S.
Morrison, Trudy G.
Article History
Received: 27 June 2017
Accepted: 12 April 2018
First Online: 15 May 2018
Competing interests
: J.C.G.B., L.M.P., R.O.O., M.C.P., L.R.F., M.S.B. from Sigmovir Biosystems Inc. (SBI) declare no competing interests. SBI is a contract research organization and perform vaccine and therapeutic studies on RSV using the cotton rat model. T.G.M., L.M., and the University of Massachusetts Medical School (UMASS) have a patent on use of NDV VLPs as vaccine platforms. They have also pending patent applications on incorporation of RSV glycoproteins into VLPs.